The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications
Open accessAbstract
Pharmacovigilance contributes to health care. However, direct access to the underlying data for academic institutions and individual physicians or pharmacists is intricate, and easily employable analysis modes for everyday clinical situations are missing. This underlines the need for a tool to bring pharmacovigilance to the clinics. To address these issues, we have developed OpenVigil FDA, a novel web-based pharmacovigilance analysis tool which uses the openFDA online interface of the Food and Drug Administration (FDA) to access U.S. American and international pharmacovigilance data from the Adverse Event Reporting System (AERS). OpenVigil FDA provides disproportionality analyses to (i) identify the drug most likely evoking a new adverse event, (ii) compare two drugs concerning their safety profile, (iii) check arbitrary combinations of two drugs for unknown drug-drug interactions and (iv) enhance the relevance of results by identifying confounding factors and eliminating them using background correction. We present examples for these applications and discuss the promises and limits of pharmacovigilance, openFDA and OpenVigil FDA. OpenVigil FDA is the first public available tool to apply pharmacovigilance findings directly to real-life clinical problems. OpenVigil FDA does not require special licenses or statistical programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
The SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451
Szarfman, A., Machado, S. G., & O??Neill, R. T. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 700
Kantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L., Goh, Y.-T., Rosti, G., Nakamae, H., Gallagher, N. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70201-7 · Cited by 513
Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.50 · Cited by 393
A statistical methodology for drug–drug interaction surveillance
Norén, G. N., Sundberg, R., Bate, A., & Edwards, I. R. (2008) · Statistics in Medicine · doi:10.1002/sim.3247 · Cited by 199
Mining multi-item drug adverse effect associations in spontaneous reporting systems
Harpaz, R., Chase, H. S., & Friedman, C. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s9-s7 · Cited by 171
Hainsworth, J. D., Harvey, W. H., Pendergrass, K. B., et al. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.721 · Cited by 154
Hoffman, K. B., Kraus, C. N., Dimbil, M., & Golomb, B. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042866 · Cited by 127
Cited by
Lakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70
Azab, M., & Pasina, L. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.011 · Cited by 33
Singh, H., Natt, N. K., & Nim, D. K. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2459720 · Cited by 10
Metadata
- Authors
- Böhm, R., von Hehn, L., Herdegen, T., Klein, H.-J., Bruhn, O., Petri, H., & Höcker, J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-21
- Volume
- 11
- Issue
- 6
- Pages
- e0157753
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2472705372
- Cited by
- 256
- References
- 19
- FWCI
- 14.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications. https://app.cochat.ai/papers/10.1371/journal.pone.0157753
- The paper
- Böhm, R., von Hehn, L., Herdegen, T., Klein, H.-J., Bruhn, O., Petri, H., & Höcker, J. (2016). OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications. PLOS ONE. https://doi.org/10.1371/journal.pone.0157753
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.